What is BlueOcean (BOV)?
BlueOcean Ventures is a Swiss venture capital firm which specializes in investing in ventures from the medical field and has developed multiple MedTech funds over the past decade. For the first time, BlueOcean has decided to hold an STO in order to give the investors the possibility of buying a tradable token (BOV) in the highly illiquid asset class of European Medtech and life science venture capital investments.
The MedTech field has recorded more than 12,000 patents filed in 2016, with over 40% of these originating from Europe. What’s more, of the over $1 billion invested every year in Swiss startups, $600 million of this is directed towards healthcare.
However, due to a large amount of money and companies entering the industry, it is not easy to filter which start-ups are truly promising, and which aren’t. This process requires quite a bit of experience in various fields ranging from medical to legal, financial and more.
Another obstacle is the fact that many investment funds are unable to take part in private equity.
These problems consequently lead to many of the best opportunities remaining either hard to notice or simply out of reach.
To solve these problems, and to achieve their goal of expansion and increased exposure, BlueOcean has decided to host an STO. This STO will provide accredited investors the ability to invest in pre-vetted start-ups. This means that they can leverage the wide range of skills the BlueOcean team gathers.
By utilizing blockchain technology, the investors in the fund will profit from not only increased transparency but also from increased levels of liquidity. There is no lock-up period on the BlueOcean tokens (BOV), so investors will be able to trade their tokens on secondary markets in a short amount of time.
If you’re interested in learning more, you can do so by reading the whitepaper here: https://blueoceanvc.docsend.com/view/gcphhck
The Blue Ocean Ventures core team consists of seven people led by Emmanuel de Watteville – the General Partner and Co-Founder, and General Partner Thomas Zehnder. The team has already proven its competence and professionalism by achievements in the field.
To see the rest of the team and advisory board, check in here: https://blueocean.swiss/#team
The community around it
- Telegram: 23 members.
Here are some of the highlights from their Medium blog:
- How BlueOcean Ventures Adds Value To Portfolio Companies
- Blue Ocean Ventures — How we select companies for investment
- Main Token Sale start date: October 15, 2018
- Main Token Sale end date: December 21, 2018
- Total Token Supply: 50,000,000
- Total Tokens Offered: 25,000,000
- Hard Cap: $33 million USD
- Soft Cap: $3.2 million USD
- Token Symbol: BOV
- Token Sale Price: 1 BOV = $1.00 USD
- Blockchain Used: Ethereum
- Token Standard: ERC20
- Token Type: Security
- 81.6% to the Token Sale
- 3.4% to the Sale referral program
- 15% to SwissVCToken’s team, employees, and partners.
The intended use of funds
- 9% Provision 7Y Operation exp SVCT
- 3% Minimum Reserve for Liquidity & Exchanges
- 3% ICO Set up Costs
- 85% Subscription BlueOcean Ventures II
- December 2018: End of the STO. 100% of the STO net proceeds will be invested into BlueOcean Ventures II
- Beginning of 2019: BOV token trades on various exchanges and BlueOcean Ventures II has a portfolio of six startups
- 2020/2021: BlueOcean Ventures II has a portfolio of eight to 12 companies. Initial expected proceed to token holders from the first sale of a portfolio company
- 2025: BlueOcean Ventures II will be closed, all remaining assets distributed to the investors
BlueOcean Ventures is indeed what its team boasts with – the first tokenized MedTech VC fund. Therefore it is very difficult finding projects with any similarities to it. The only similar projects worth mentioning are not tokenized, and these include LSP Health Economics Fund 2 (LSP HEF 2) and 360 Capital Partners, a VC fund that in its portfolio has four MedTech companies.
LSP HEF 2 invests in companies with products or technologies that improve the quality of healthcare and reduce its cost. LSP has launched the €112 million EUR LSP HEF fund in 2012 and became the first European private equity fund fully dedicated to medical innovations that improve the quality of care and reduce costs. After the successful investment and exit strategy of its first health economic fund, the company decided to launch the LSP HEF 2 in 2017, with €280 million EUR, becoming the largest fund in Europe dedicated to MedTech.
360 Capital Partners is a VC firm investing in innovative deep-tech and digital enterprises across Europe. Based in Paris and Milan, it has a 20-year track record of supporting talented tech entrepreneurs in developing ambitious and disruptive companies across a wide array of sectors. It covers a wide range of companies and also includes four MedTech companies in its portfolio: Withings, Thereson, Invendo Medical, and Bmeye.
However, since neither of these two projects is a purely tokenized MedTech VC fund, they can hardly be considered as true competition to BlueOcean Ventures II.
MedTech is a large industry in Europe alone and is quite broad in its description. Those within the industry could be credited with developing next-gen pacemakers, atrial valves, insulin delivery vehicles, and even deep brain stimulation methods. This is why funding is incredibly important and which is where BlueOcean Ventures has a huge role. It is an asset-backed, liquid fund, accessible to both cryptocurrency and fiat holders. A revolutionary firm in its field with an experienced team behind it, BlueOcean Ventures undoubtedly has a great starting position and is bound to produce success in the future.
That said, they should really invest more time and effort into communicating with the wider public as they only have a Medium blog with several posts and a Telegram channel with only 23 participants.
By Sead Fadilpasic